Product Description
Mechanisms of Action: Ceruloplasmin Cofactor, Cytochrome C Oxidase Cofactor, LOX Cofactor, SOD Cofactor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Colombia | Malaysia | Taiwan | United Arab Emirates | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: American Regent
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12625001178437 |
ACTRN12625001178437 | N/A |
Not yet recruiting |
Healthy Volunteers |
2026-04-30 |
2025-10-30 |
Treatments |
|
NCT05661682 |
TE20001 | P4 |
Withdrawn |
Other |
2025-10-31 |
2025-02-13 |
Primary Endpoints |
|
NCT05677126 |
TE20002 | P4 |
Withdrawn |
Other |
2024-08-01 |
2024-11-16 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/03/2025 |
News Article |
WIT Legal Releases 2nd Annual Report on Trends in Hatch-Waxman Litigation |
|
02/28/2022 |
News Article |
Hydrazine Hydrate Market to be worth US$ 683.1 Million by the year 2030 - Comprehensive Research Report by FMI |
|
09/02/2021 |
News Article |
American Regent Launches Multrys™ (trace elements injection 4*, USP) |
|
09/30/2020 |
News Article |
American Regent Introduces Tralement™ (trace elements injection 4*, USP) |